Reevaluating clinical measurement tools in therapeutic trials; Time to make a rasch decision?

Neurology

Volumn 83, Issue 23, 2014, Pages 2104-2105

  Smith, Gordon ^a   Burns, Ted M ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; EDITORIAL; EXPERIMENTAL THERAPY; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATORY NEUROPATHY CAUSE AND TREATMENT OVERALL NEUROPATHY LIMITATION SCALE; INFLAMMATORY RASCH-BUILT OVERALL DISABILITY SCALE; MYASTHENIA GRAVIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SELF REPORT; STUDY DESIGN; FEMALE; MALE; PATHOPHYSIOLOGY; POLYNEUROPATHIES;

FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84925283506     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001058     Document Type: Editorial

References (5)

1. Draak THP, Vanhoutte EK, van Nes SI, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 2014;83:2124-2132.
2. Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: A closer look at the minimal clinically important difference (MCID). J Man Manip Ther 2012; 20:160-166.
3. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-1532.
4. Barnett C, Wilson G, Barth D, Katzberg HD, Bril V. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psych 2013;84:94-97.
5. Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality of life and treatment targets in myasthenia gravis. Muscle Nerve 2014;50:493-500.